This suggested one mechanism of how PSMA overexpression could drive prostate cancer growth and indicated that disrupting the interaction between PSMA and the scaffold might have therapeutic potential for patients with PSMA-positive prostate cancer. Here, FOLH1 is linked to prostate carcinoma.